Allogene Therapeutics Inc... (ALLO)
NASDAQ: ALLO
· Real-Time Price · USD
1.27
0.00 (0.00%)
At close: Oct 16, 2025, 3:59 PM
1.26
-0.78%
After-hours: Oct 16, 2025, 06:59 PM EDT
0.00% (1D)
| Bid | 1.25 |
| Market Cap | 281.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -236.91M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -1.15 |
| Forward PE | -1.4 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.29 |
| Volume | 3,301,620 |
| Avg. Volume (20D) | 4,008,973 |
| Open | 1.27 |
| Previous Close | 1.27 |
| Day's Range | 1.25 - 1.38 |
| 52-Week Range | 0.86 - 3.78 |
| Beta | 0.43 |
| Ex-Dividend Date | n/a |
About ALLO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALLO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAllogene Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
-18.54%
Allogene Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
4 months ago
+8.55%
Allogene Therapeutics shares are trading higher after the company provided updates for its Phase 1 TRAVERSE study of ALLO-316.
2 months ago · seekingalpha.com
Allogene Therapeutics: Important Catalysts Guided For Early 2026I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains...
2 months ago · seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call TranscriptAllogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy ...
